Literature DB >> 19880064

First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009.

Ross A Soo1, Benjamin O Anderson, Byoung Chul Cho, Chih-Hsin Yang, Meilin Liao, Wan-Teck Lim, Peter Goldstraw, Tony S Mok.   

Abstract

Non-small-cell lung cancer (NSCLC) is an increasing global challenge, especially in low-income countries. Most guidelines for the management of advanced-stage NSCLC have limited effect in countries with resource constraints. Following a systematic literature search, we present an overview of the management of advanced-stage NSCLC in the first-line setting, discuss resources required for systemic therapy, and provide treatment recommendations stratified to four resources levels. Treatment guidelines appropriate for different resource levels offer a realistic approach to management of advanced-stage NSCLC, by recognising the limitations of a particular health-care system. Although there are many barriers to cancer control in low-resource countries, these can be overcome by using measures that are culturally appropriate, economically feasible, and evidence-based. Initiatives include strategic planning, tobacco control, training of health-care workers, access to therapeutic agents, acquisition of information, public education, and alliances with established institutions and international organisations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19880064     DOI: 10.1016/S1470-2045(09)70238-4

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  6 in total

Review 1.  Defining timeliness in care for patients with lung cancer: a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Muhammad Aziz Rahman
Journal:  BMJ Open       Date:  2022-04-07       Impact factor: 2.692

2.  Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer.

Authors:  Georg Holgersson; Martin Sandelin; Even Hoye; Stefan Bergström; Roger Henriksson; Simon Ekman; Jan Nyman; Martin Helsing; Signe Friesland; Margareta Holgersson; Kristina Lamberg Lundström; Christer Janson; Elisabet Birath; Charlotte Mörth; Thomas Blystad; Sven-Börje Ewers; Britta Löden; Michael Bergqvist
Journal:  Med Oncol       Date:  2012-05-08       Impact factor: 3.064

Review 3.  A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.

Authors:  Sheila X Soh; Fahad J Siddiqui; John C Allen; Go Woon Kim; Jae Cheol Lee; Yasushi Yatabe; Manabu Soda; Hiroyuki Mano; Ross A Soo; Tan-Min Chin; Hiromichi Ebi; Seiji Yano; Keitaro Matsuo; Xiaomin Niu; Shun Lu; Kazutoshi Isobe; Jih-Hsiang Lee; James C Yang; Mingchuan Zhao; Caicun Zhou; June-Koo Lee; Se-Hoon Lee; Ji Yun Lee; Myung-Ju Ahn; Tira J Tan; Daniel S Tan; Eng-Huat Tan; S Tiong Ong; Wan-Teck Lim
Journal:  Oncotarget       Date:  2017-06-20

4.  Resource-Stratified Guidelines for Cancer Management: Correction and Commentary.

Authors:  Benjamin O Anderson; Catherine Duggan
Journal:  J Glob Oncol       Date:  2016-08-31

5.  Investigating efficacy of "microbiota modulation of the gut-lung Axis" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.

Authors:  Qing Xia; Guojie Chen; Yanbei Ren; Tiansheng Zheng; Changxing Shen; Ming Li; Xiangyun Chen; Hong Zhai; Zhuang Li; Jianfang Xu; Aiqin Gu; Meiling Jin; Lihong Fan
Journal:  BMC Cancer       Date:  2021-06-22       Impact factor: 4.430

6.  Defining timeliness in care for patients with lung cancer: protocol for a scoping review.

Authors:  Adnan Ansar; Virginia Lewis; Christine Faye McDonald; Chaojie Liu; Aziz Rahman
Journal:  BMJ Open       Date:  2020-11-04       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.